Should you buy Adaptimmune Therapeutics plc stock? (NasdaqGS:ADAP). Let's see how it does in our automated value investing analysis system.
Hmm, we can't give any reliable projection for Adaptimmune Therapeutics plc's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
(Adaptimmune Therapeutics plc stock price per share)
|PE Ratio versus Sector||100% lower than other Healthcare stocks|
|PE Ratio versus Industry||100% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||18%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 1,512,930 shares shorted. With 125,507,004 shares available for purchase and an average trading volume over the past 10 trading days of 812,683, it would take at least 1.862 days for all of the short holders to cover their shorts.
Based on our analysis, we believe that you should not buy Adaptimmune Therapeutics plc right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Adaptimmune Therapeutics plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles